Dimerix Bioscience Pty Ltd

Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets.

Dimerix is currently developing its proprietary product DMX-200 for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. The company is also developing DMX-200 for two different kidney diseases, Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS).

Dimerix's lead clinical drug candidate, DMX-200, was selected for inclusion in the global REMAP CAP study for patients with Acute Respiratory Distress Syndrome associated with COVID-19. DMX-200 therapy is aimed at reducing damage from inflammatory immune cells by blocking their signalling and limiting subsequent movement. Patients hospitalised with COVID-19 commonly have acute lung dysfunction due to the immune response to the virus. Global experts see DMX-200 as a compelling treatment option to limit inflammation in the lungs during infection of the SARS-CoV2 virus.

REMAP-CAP is a global WHO-endorsed study designed to rapidly generate evidence for treatments in patients with respiratory distress associated with COVID-19.

BTB Round: Three

State: Victoria


  • MTPConnect Grant: $1,122,500
  • Industry Contribution: $2,845,986

Duration: September 2020 – November 2021

Visit Dimerix for more information  |  Twitter: @dimerixltd  |  LinkedIn: Dimerix Limited

Contact: Dr Nina Webster

Podcast: Dimerix investigates new treatment for COVID-19 complications (31 May 2022)